I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Christopher D. Roberts net worth and biography

Christopher Roberts Biography and Net Worth

Insider of Black Diamond Therapeutics

Dr. Christopher D. Roberts Ph.D. serves as Chief Scientific Officer of the Company. Prior to joining us, from April 2017 to August 2019, Dr. Roberts was Entrepreneur in Residence at S.R. One Limited, the corporate venture capital arm of GlaxoSmithKline plc. Previously, from April 2015 to March 2017, Dr. Roberts served as Vice President of Chemistry and Early Development at Syros Pharmaceuticals, Inc., a publicly-traded biotechnology company, where he built and led various discovery and development functions and helped guide two oncology assets into clinical development. Prior to joining Syros, from January 2009 to March 2015, Dr. Roberts held numerous positions of increasing responsibility at GSK, including Vice President and Head of the Host Defense Discovery Performance Unit. Dr. Roberts graduated with a B.A. in Chemistry from Whitworth University and earned his Ph.D. in Organic Chemistry from the University of California, Riverside, followed by a post-doctoral fellowship at the University of Bern, Switzerland.

What is Christopher D. Roberts' net worth?: The estimated net worth of Christopher D. Roberts is at least $14,934.00 as of May 3rd, 2021. Dr. Roberts owns 5,700 shares of Black Diamond Therapeutics stock worth more than $14,934 as of November 17th. This net worth evaluation does not reflect any other investments that Dr. Roberts may own. Learn More about Christopher D. Roberts' net worth.
How do I contact Christopher D. Roberts?: The corporate mailing address for Dr. Roberts and other Black Diamond Therapeutics executives is 139 MAIN STREET, CAMBRIDGE MA, 02142. Black Diamond Therapeutics can also be reached via phone at 617-252-0848 and via email at [email protected]. Learn More on Christopher D. Roberts' contact information.
Has Christopher D. Roberts been buying or selling shares of Black Diamond Therapeutics?: Christopher D. Roberts has not been actively trading shares of Black Diamond Therapeutics during the last quarter. Most recently, Christopher D. Roberts sold 2,500 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $26.64, for a transaction totalling $66,600.00. Following the completion of the sale, the insider now directly owns 5,700 shares of the company's stock, valued at $151,848. Learn More on Christopher D. Roberts' trading history.
Who are Black Diamond Therapeutics' active insiders?: Black Diamond Therapeutics' insider roster includes Brent Hatzis-Schoch (Insider), and Christopher Roberts (Insider). Learn More on Black Diamond Therapeutics' active insiders.

Christopher D. Roberts Insider Trading History at Black Diamond Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/3/2021	Sell	2,500	$26.64	$66,600.00	5,700
4/5/2021	Sell	2,500	$25.54	$63,850.00	5,700
3/3/2021	Sell	2,500	$26.10	$65,250.00
2/3/2021	Sell	2,500	$25.35	$63,375.00	5,700
1/4/2021	Sell	2,500	$31.41	$78,525.00	5,700
12/3/2020	Sell	2,500	$32.42	$81,050.00	2,500
10/5/2020	Sell	2,500	$31.28	$78,200.00	2,500
9/3/2020	Sell	2,500	$29.59	$73,975.00	2,500

Christopher D. Roberts Buying and Selling Activity at Black Diamond Therapeutics

Black Diamond Therapeutics Company Overview

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $2.62

$2.62

$2.86

50 Day Range

MA: $3.83

$2.62

$6.19

2 Week Range

Now: $2.62

$2.09

$7.66

Volume

442,206 shs

Average Volume

598,251 shs

Market Capitalization

$148.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.51

I was wrong. Dead wrong.

From Porter & Company | Ad